A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
Recruiting now · Phase 3
Conditions studied: Neuromyelitis Optica Spectrum Disorder, NMOSD
In brief
This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD). Efficacy, safety, tolerability, and pharmacodynamics will be evaluated in a descriptive manner, given the small number of patients who will be enrolled in this study.
Key facts
- Study ID
- NCT05199688
- Run by
- Hoffmann-La Roche
- People needed
- 8
- Starts
- 2026-05-06
- Expected to finish
- 2029-09-12
- Last updated by the study team
- 2026-07-09
Who can join
Age: 2 and older, up to 11. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age at screening 2-11 years, inclusive
- Body weight at screening >=10 kg
- For female patients of childbearing potential (postmenarchal): agreement to either remain completely abstinent (refrain from heterosexual intercourse) or to use a reliable means of contraception
- Diagnosed as having NMOSD with AQP4 antibody seropositive status as defined by the Wingerchuk 2015 criteria Clinical evidence of at least one documented attack (including first attack) in the last year prior to screening
- Neurological stability for >=30 days prior to both screening and baseline
- Expanded Disability Status Scale (EDSS) 0 to 6.5
- For patients receiving a baseline immunosuppressant treatment and planning to continue on these therapies, treatment must be at stable dose for 4 weeks prior to baseline
You may not qualify if…
- Pregnancy or lactation
- Evidence of other demyelinating disease mimicking NMOSD
- Active or presence of recurrent bacterial, viral, fungal, mycobacterial infection, or other infection at baseline
- Evidence of chronic active hepatitis B or C
- Evidence of untreated latent or active tuberculosis (TB)
- Receipt of a live or live-attenuated vaccine within 6 weeks prior to baseline
- History of severe allergic reaction to a biologic agent
Where it is running
- Great Ormond Street Hospital for Children — London, United Kingdom (enrolling)
- Hospital de Pediatría S.A.M.I.C.- Prof. Dr. Juan P. Garrahan — Ciudad Autonoma Buenos Aires, Argentina (enrolling)
- Clinica Universitaria Reina Fabiola — Córdoba, Argentina (enrolling)
- Guangzhou Women and Children's Medical Center — Guangzhou, Guangdong, China (enrolling)
- Children's Hospital of Fudan University — Shanghai, Shanghai Municipality, China (enrolling)
- Centre Hospitalier Universitaire de Bicêtre — Le Kremlin-Bicêtre, France (enrolling)
- IRCCS Ospedale Pediatrico Bambino Gesù - INCIPIT - PIN — Rome, Lazio, Italy (enrolling)
- Fondazione Istituto Neurologico Mondino IRCCS — Pavia, Lombardy, Italy (enrolling)
- Grupo Medico Camino — DF, Mexico CITY (federal District), Mexico (enrolling)
- Children's Hospital Colorado. — Denver, Colorado, United States (enrolling)
- Instytut "Pomnik - Centrum Zdrowia Dziecka" — Warsaw, Poland (enrolling)
- Kocaeli University Research and Application Hospit — Kocaeli, Turkey (Türkiye) (enrolling)
- Uniwersyteckie Centrum Kliniczne — Gdansk, Poland
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.